COVID-19 increases a person's risk of cardiovascular problems: how common is chronic heart failure in SARS-CoV-2 patients? a case report.

UNLABELLED

The coronavirus disease of 2019 (COVID-19) infection typically affects the lungs but can also cause life-threatening heart issues. Heart failure is a common condition that can occur either with an existing heart condition or de novo as part of the clinical course of COVID-19.

CASE PRESENTATION

On 11 October 2022, a 60-year-old middle-aged black African woman widow was admitted with a history of muscular weakness for 2 days, a lack of appetite, and occasional vomiting for 1 day. She arrived at the emergency room after complaining for 2 days of peeing less than usual, a fast heartbeat, swelling in the feet, pink blood-tinged mucus, fever, headache, dehydration, a nonproductive cough, and shortness of breath. The left ventricular ejection fraction was 43% on the echocardiogram. Routine reverse transcription polymerase chain reaction testing was performed in the emergency room; she tested COVID-19 positive. To treat her proven COVID-19 infection, she received subcutaneous enoxaparin 80 mg every 12 h as prophylaxis for deep venous thromboembolism.

CLINICAL DISCUSSION

A COVID-19 infection can induce cardiac failure and arrhythmias, as well as cause direct harm to the heart. This study explains how enoxaparin has dual benefits in this case report: it reduces the risk of venous thromboembolism in the COVID-19 hospitalized case and prevents death and cardiac ischemia in myocardial infarction.

CONCLUSION

Higher mortality and more frequent acute decompensation may be caused by the capacity of severe acute respiratory syndrome associated coronavirus 2 to cause myocardial injury, as well as by patients with chronic heart failure's lower baseline features, decreased cardiopulmonary reserve, and susceptibility for myocardial injury.